Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, randomised, placebo controlled trial to evaluate the effect of Melatonin as an adjuvant agent at Induction of labour on the rate of induction of labour failure in healthy, pregnant women undergoing cervical ripening prior to induction of labour for prolonged pregnancy.

Next Previous
X
Search
Trial Profile

A double blind, randomised, placebo controlled trial to evaluate the effect of Melatonin as an adjuvant agent at Induction of labour on the rate of induction of labour failure in healthy, pregnant women undergoing cervical ripening prior to induction of labour for prolonged pregnancy.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melatonin (Primary) ; Oxytocin
  • Indications Labour induction
  • Focus Therapeutic Use
  • Acronyms MILO

    • Most Recent Events

    • 21 Jan 2022 Actual date of last participant enrolled is 14 Aug 2021 according to Australian New Zealand Clinical Trials Registry record.
    • 21 Jan 2022 Status changed from recruiting to discontinued.
    • 15 Jun 2018 Planned number of patients changed from 796 to 722.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top